For the year ending 2025-12-31, AGEN had -$39,361K decrease in cash & cash equivalents over the period. -$77,201K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues | 114,196 |
| External expenses | 70,213 |
| Payroll related expenses | 39,664 |
| Other operating expenses | 24,488 |
| Operating loss | -20,169 |
| Interest expense | 55,618 |
| Interest income | 345 |
| Other income | 72,359 |
| Net loss | -3,083 |
| Depreciation and amortization | 9,999 |
| Share-based compensation | 13,770 |
| Non-cash royalty revenue | 108,588 |
| Non-cash interest expense | 54,440 |
| Loss (gain) on sale or disposal of assets, net | -937 |
| Gain from deconsolidation of mink therapeutics, inc | 100,924 |
| Loss on impairment of assets | 234 |
| Gain on forgiveness of liability | 0 |
| Gain on lease terminations | 0 |
| Unrealized loss on long-term investments | -26,119 |
| Fair value adjustments | 387 |
| Other, net | -2,954 |
| Accounts receivable | 1,728 |
| Prepaid expenses | -1,260 |
| Accounts payable | 23,500 |
| Deferred revenue | 1 |
| Accrued liabilities and other current liabilities | 4,499 |
| Other operating assets and liabilities | 198 |
| Net cash used in operating activities | -77,195 |
| Proceeds from sale of property, plant and equipment | 359 |
| Purchases of property, plant and equipment | 6 |
| Purchases of available-for-sale securities | 0 |
| Proceeds from sale of available-for-sale securities | 0 |
| Purchase of long-term investment | 0 |
| Proceeds from sale of long-term investment | 841 |
| Net cash provided by investing activities | 1,194 |
| Net proceeds from sale of equity | 36,136 |
| Net proceeds from sale of subsidiary shares in private placement | 0 |
| Proceeds from employee stock purchases and option exercises | 169 |
| Purchase of treasury shares to satisfy tax withholdings | 87 |
| Purchase of subsidiary shares | 0 |
| Proceeds from ligand purchase agreement, net of expenses | 0 |
| Proceeds from the issuance of long-term debt, net | 12,500 |
| Impact to cash resulting from deconsolidation certain subsidiaries | 1,974 |
| Payment of long-term debt | 2,500 |
| Payment of finance lease obligations | 7,651 |
| Net cash provided by financing activities | 36,593 |
| Effect of exchange rate changes on cash | 47 |
| Net decrease in cash, cash equivalents and restricted cash | -39,361 |
| Cash, cash equivalents and restricted cash, beginning of period | 44,071 |
| Cash, cash equivalents and restricted cash, end of period | 4,710 |
AGENUS INC (AGEN)
AGENUS INC (AGEN)